John R Burnett

Summary

Affiliation: Western Australia
Country: Australia

Publications

  1. ncbi request reprint Apolipoprotein B metabolism: tracer kinetics, models, and metabolic studies
    John R Burnett
    Department of Core Clinical Pathology and Biochemistry, Royal Perth Hospital, University of Western Australia, Australia
    Crit Rev Clin Lab Sci 39:89-137. 2002
  2. ncbi request reprint Cholesterol absorption inhibitors as a therapeutic option for hypercholesterolaemia
    John R Burnett
    Royal Perth Hospital, Department of Core Clinical Pathology and Biochemistry, PathWest Laboratory Medicine WA, Wellington Street Campus, GPO Box X2213, Perth, WA 6847, Australia
    Expert Opin Investig Drugs 15:1337-51. 2006
  3. ncbi request reprint Alipogene tiparvovec, an adeno-associated virus encoding the Ser(447)X variant of the human lipoprotein lipase gene for the treatment of patients with lipoprotein lipase deficiency
    John R Burnett
    Royal Perth Hospital, Department of Core Clinical Pathology and Biochemistry, PathWest Laboratory Medicine WA, Wellington Street, GPO Box X2213, Perth, WA 6847, Australia
    Curr Opin Mol Ther 11:681-91. 2009
  4. ncbi request reprint Drug evaluation: The MTP inhibitor JTT-130 as a potential treatment for hyperlipidemia
    John R Burnett
    Department of Core Clinical Pathology and Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital and School of Medicine and Pharmacology, University of Western Australia, Perth, WA 6847, Australia
    IDrugs 9:495-9. 2006
  5. ncbi request reprint Drug evaluation: ISIS-301012, an antisense oligonucleotide for the treatment of hypercholesterolemia
    John R Burnett
    Royal Perth Hospital, Department of Core Clinical Pathology and Biochemistry, PathWest Laboratory Medicine WA, Wellington Street, GPO Box X2213, Perth, WA 6847, Australia
    Curr Opin Mol Ther 8:461-7. 2006
  6. ncbi request reprint Torcetrapib + atorvastatin (Pfizer)
    John R Burnett
    Royal Perth Hospital, Department of Core Clinical Pathology and Biochemistry, PathWest Laboratory Medicine WA, Perth, WA 6847, Australia
    Curr Opin Investig Drugs 6:944-50. 2005
  7. ncbi request reprint MTP inhibition as a treatment for dyslipidaemias: time to deliver or empty promises?
    John R Burnett
    PathWest Laboratory Medicine, Department of Core Clinical Pathology and Biochemistry, Royal Perth Hospital, Wellington Street Campus, GPO Box X2213, Perth, WA 6847, Australia
    Expert Opin Ther Targets 11:181-9. 2007
  8. ncbi request reprint Drug evaluation: TAK-475--an oral inhibitor of squalene synthase for hyperlipidemia
    John R Burnett
    Department of Core Clinical Pathology and Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital, Australia
    Curr Opin Investig Drugs 7:850-6. 2006
  9. ncbi request reprint Cardiovascular disease and osteoporosis: is there a link between lipids and bone?
    John R Burnett
    Department of Core Clinical Pathology and Biochemistry, Royal Perth Hospital, WA, Australia
    Ann Clin Biochem 39:203-10. 2002
  10. ncbi request reprint FM-VP4 Forbes Medi-Tech
    John R Burnett
    Department of Core Clinical Pathology and Biochemistry, Royal Perth Hospital, School of Surgery and Pathology, University of Western Australia, Wellington Street, GPO Box X2213, Perth, WA 6847, Australia
    Curr Opin Investig Drugs 4:1120-5. 2003

Collaborators

Detail Information

Publications56

  1. ncbi request reprint Apolipoprotein B metabolism: tracer kinetics, models, and metabolic studies
    John R Burnett
    Department of Core Clinical Pathology and Biochemistry, Royal Perth Hospital, University of Western Australia, Australia
    Crit Rev Clin Lab Sci 39:89-137. 2002
    ..New developments and significant advances over the last decade are discussed...
  2. ncbi request reprint Cholesterol absorption inhibitors as a therapeutic option for hypercholesterolaemia
    John R Burnett
    Royal Perth Hospital, Department of Core Clinical Pathology and Biochemistry, PathWest Laboratory Medicine WA, Wellington Street Campus, GPO Box X2213, Perth, WA 6847, Australia
    Expert Opin Investig Drugs 15:1337-51. 2006
    ..This review focuses on the recent progress in the molecular mechanisms of intestinal cholesterol absorption and transport, and novel therapeutic approaches to inhibit the cholesterol absorption process...
  3. ncbi request reprint Alipogene tiparvovec, an adeno-associated virus encoding the Ser(447)X variant of the human lipoprotein lipase gene for the treatment of patients with lipoprotein lipase deficiency
    John R Burnett
    Royal Perth Hospital, Department of Core Clinical Pathology and Biochemistry, PathWest Laboratory Medicine WA, Wellington Street, GPO Box X2213, Perth, WA 6847, Australia
    Curr Opin Mol Ther 11:681-91. 2009
    ..The compound is also under investigation for the treatment of type V hyperlipoproteinemia, Syndrome X and non-alcoholic steatohepatitis...
  4. ncbi request reprint Drug evaluation: The MTP inhibitor JTT-130 as a potential treatment for hyperlipidemia
    John R Burnett
    Department of Core Clinical Pathology and Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital and School of Medicine and Pharmacology, University of Western Australia, Perth, WA 6847, Australia
    IDrugs 9:495-9. 2006
    ..By August 2005, the compound was undergoing a phase II clinical trial in Japan, as well as a phase I trial in Europe...
  5. ncbi request reprint Drug evaluation: ISIS-301012, an antisense oligonucleotide for the treatment of hypercholesterolemia
    John R Burnett
    Royal Perth Hospital, Department of Core Clinical Pathology and Biochemistry, PathWest Laboratory Medicine WA, Wellington Street, GPO Box X2213, Perth, WA 6847, Australia
    Curr Opin Mol Ther 8:461-7. 2006
    ..A subcutaneous injectable formulation is currently undergoing phase 11 clinical trials, while phase I trials are underway with an oral formulation of the drug...
  6. ncbi request reprint Torcetrapib + atorvastatin (Pfizer)
    John R Burnett
    Royal Perth Hospital, Department of Core Clinical Pathology and Biochemistry, PathWest Laboratory Medicine WA, Perth, WA 6847, Australia
    Curr Opin Investig Drugs 6:944-50. 2005
    ..As of April 2005, phase III trials were ongoing...
  7. ncbi request reprint MTP inhibition as a treatment for dyslipidaemias: time to deliver or empty promises?
    John R Burnett
    PathWest Laboratory Medicine, Department of Core Clinical Pathology and Biochemistry, Royal Perth Hospital, Wellington Street Campus, GPO Box X2213, Perth, WA 6847, Australia
    Expert Opin Ther Targets 11:181-9. 2007
    ..However, certain safety issues with these agents need resolving, particularly fatty liver disease...
  8. ncbi request reprint Drug evaluation: TAK-475--an oral inhibitor of squalene synthase for hyperlipidemia
    John R Burnett
    Department of Core Clinical Pathology and Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital, Australia
    Curr Opin Investig Drugs 7:850-6. 2006
    ..By March 2005, TAK-475 was undergoing phase III clinical trials in the US and Europe...
  9. ncbi request reprint Cardiovascular disease and osteoporosis: is there a link between lipids and bone?
    John R Burnett
    Department of Core Clinical Pathology and Biochemistry, Royal Perth Hospital, WA, Australia
    Ann Clin Biochem 39:203-10. 2002
    ....
  10. ncbi request reprint FM-VP4 Forbes Medi-Tech
    John R Burnett
    Department of Core Clinical Pathology and Biochemistry, Royal Perth Hospital, School of Surgery and Pathology, University of Western Australia, Wellington Street, GPO Box X2213, Perth, WA 6847, Australia
    Curr Opin Investig Drugs 4:1120-5. 2003
    ..By March 2002, FM-VP4 had entered phase I clinical trials and phase II trials were underway by late 2002...
  11. ncbi request reprint Eflucimibe. Pierre Fabre/Eli Lilly
    John R Burnett
    Department of Core Clinical Pathology and Biochemistry, Royal Perth Hospital and School of Surgery and Pathology, University of Western Australia, Wellington Street, GPO Box X2213, Perth, Western Australia 6847, Australia
    Curr Opin Investig Drugs 4:347-51. 2003
    ..Phase II clinical trials commenced during 2002...
  12. ncbi request reprint Missense mutations in APOB within the betaalpha1 domain of human APOB-100 result in impaired secretion of ApoB and ApoB-containing lipoproteins in familial hypobetalipoproteinemia
    John R Burnett
    Department of Core Clinical Pathology and Biochemistry, Royal Perth Hospital, Australia
    J Biol Chem 282:24270-83. 2007
    ..Thus, proper folding of the alpha-helical domain of apoB-100 is essential for efficient secretion...
  13. ncbi request reprint Sapropterin dihydrochloride (Kuvan/phenoptin), an orally active synthetic form of BH4 for the treatment of phenylketonuria
    John R Burnett
    Department of Core Clinical Pathology and Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital and School of Medicine and Pharmacology, University of Western Australia, Perth, WA 6847, Australia
    IDrugs 10:805-13. 2007
    ..According to Thomson Scientific's Strategic Drugs Database (SDdb), the worldwide consensus forecast values for Kuvan are approximately US $120, 190 and 260 million for 2008, 2009 and 2010, respectively...
  14. ncbi request reprint Avasimibe Pfizer
    John R Burnett
    Department of Core Clinical Pathology and Biochemistry, Division of Laboratory Medicine, Royal Perth Hospital, Wellington Street, Perth, WA 6847, Australia
    Curr Opin Investig Drugs 3:1328-33. 2002
    ..The compound is currently undergoing phase III clinical trials [371470]...
  15. ncbi request reprint A novel nontruncating APOB gene mutation, R463W, causes familial hypobetalipoproteinemia
    John R Burnett
    Department of Core Clinical Pathology and Biochemistry, Royal Perth Hospital and Department of Pathology, University of Western Australia, Perth WA 6847, Western Australia, Australia
    J Biol Chem 278:13442-52. 2003
    ..Thus, the naturally occurring R463W mutant reveals a key local domain governing assembly and secretion of apoB-containing lipoproteins...
  16. doi request reprint Genetic analysis of familial hypercholesterolaemia in Western Australia
    Amanda J Hooper
    Cardiovascular Genetics Laboratory, Department of Core Clinical Pathology and Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital, Perth, Australia
    Atherosclerosis 224:430-4. 2012
    ..To determine the spectrum of mutations associated with familial hypercholesterolaemia (FH) and their detection rate in the FH Western Australia (FHWA) Program...
  17. pmc Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia
    Damon A Bell
    Department of Core Clinical Pathology and Biochemistry, PathWest Laboratory Medicine, Royal Perth Hospital, Perth, Western Australia, Australia
    Vasc Health Risk Manag 8:651-9. 2012
    ....
  18. doi request reprint Opportunistic screening for familial hypercholesterolaemia via a community laboratory
    Damon A Bell
    Department of Core Clinical Pathology and Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital, GPO Box X2213, Perth, WA 6847, Australia
    Ann Clin Biochem 49:534-7. 2012
    ..The majority of people with FH are currently undiagnosed. We sought to determine the ability of a community laboratory to screen for individuals with potential FH...
  19. doi request reprint Screening for familial hypercholesterolaemia
    ROBERT BENDER
    Department of Core Clinical Pathology and Biochemistry, Royal Perth Hospital, Perth, Western Australia, Australia
    Pathology 44:122-8. 2012
    ..However, for screening to be successful, medical practitioners need to be aware of the signs and diagnosis of FH and the benefits of early treatment...
  20. ncbi request reprint Postprandial lipoprotein metabolism in familial hypobetalipoproteinemia
    Amanda J Hooper
    Department of Core Clinical Pathology and Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital, Wellington Street, GPO Box X2213, Perth, and School of Medicine and Pharmacology, University of Western Australia, Crawley, Australia
    J Clin Endocrinol Metab 92:1474-8. 2007
    ..We examined the effect of truncated apoB variants (<apoB-48) causing FHBL on postprandial triglyceride-rich lipoprotein (TRL) metabolism...
  21. ncbi request reprint The ACAT inhibitor avasimibe increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs
    John R Burnett
    Department of Core Clinical Pathology and Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital and School of Medicine and Pharmacology, University of Western Australia, Perth, Australia
    Biochim Biophys Acta 1738:10-8. 2005
    ..Thus, although avasimibe had no effect on intestinal TRL secretion, plasma TRL clearance was significantly increased; an effect that may relate to a decreased competition with hepatic VLDL for removal processes...
  22. doi request reprint Impact of interpretative commenting on lipid profiles in people at high risk of familial hypercholesterolaemia
    Damon A Bell
    Department of Clinical Biochemistry, Royal Perth Hospital, Perth, WA, Australia
    Clin Chim Acta 422:21-5. 2013
    ..However, it is currently underdiagnosed and undertreated in Australasia. We sought to investigate whether interpretative commenting on lipid profiles could improve FH detection and treatment...
  23. doi request reprint Vitamin E supplementation and hepatic drug metabolism in humans
    Michael W Clarke
    Department of Core Clinical Pathology and Biochemistry, PathWest Laboratory Medicine, Royal Perth Hospital, University of Western Australia, Perth, Western Australia, Australia
    J Cardiovasc Pharmacol 54:491-6. 2009
    ..These findings do not support the hypothesis that alpha-TOH supplementation interferes with hepatic CYP3A4-mediated drug metabolism...
  24. pmc A model of care for familial hypercholesterolaemia: key role for clinical biochemistry
    Gerald F Watts
    Lipid Disorders Clinic, Metabolic Research Centre and Department of Internal Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, WA, Australia
    Clin Biochem Rev 33:25-31. 2012
    ..An executive summary of the model of care is presented, with a commentary on its recommendations and the key role of the clinical biochemistry laboratory...
  25. doi request reprint Anti-PCSK9 therapies for the treatment of hypercholesterolemia
    Amanda J Hooper
    Royal Perth Hospital, Department of Core Clinical Pathology and Biochemistry, PathWest Laboratory Medicine WA, Perth, Western Australia
    Expert Opin Biol Ther 13:429-35. 2013
    ..PCSK9 is a novel, attractive and viable therapeutic target for the treatment of hypercholesterolemia, with human studies using a variety of anti-PCSK9 therapies underway...
  26. doi request reprint Screening for lipid disorders
    Damon A Bell
    Department of Core Clinical Pathology and Biochemistry, Royal Perth Hospital, Perth, Western Australia, Australia
    Pathology 44:115-21. 2012
    ..This review examines the role of screening in the detection and treatment of individuals with lipid disorders...
  27. doi request reprint Hypobetalipoproteinaemia secondary to chronic hepatitis C virus infection in a patient with familial hypercholesterolaemia
    Abdulhadi I Bima
    Department of Core Clinical Pathology and Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital, Perth, WA 6847, Australia
    Ann Clin Biochem 46:420-2. 2009
    ..In summary, we describe a case of HBL secondary to chronic HCV infection in a patient with FH, confirmed by mutational analysis...
  28. doi request reprint A novel missense LIPA gene mutation, N98S, in a patient with cholesteryl ester storage disease
    Amanda J Hooper
    Department of Core Clinical Pathology and Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital, Perth, Australia
    Clin Chim Acta 398:152-4. 2008
    ..In summary, we describe a CESD patient compound heterozygous for the LIPA exon 8 splice junction mutation and a novel missense mutation, N98S...
  29. ncbi request reprint Vitamin E in human health and disease
    Michael W Clarke
    School of Medicine and Pharmacology, University of Western Australia, Crawley, WA, Australia
    Crit Rev Clin Lab Sci 45:417-50. 2008
    ..Other possibilities include an adverse effect of alpha-TOH on blood pressure in high-risk populations. Because of the wide popularity and use of vitamin E supplements, further research into potential adverse effects is clearly warranted...
  30. doi request reprint A novel ABCA1 nonsense mutation, R1270X, in Tangier disease associated with an unrecognised bleeding tendency
    Amanda J Hooper
    Department of Core Clinical Pathology and Biochemistry, Royal Perth Hospital, Perth, Australia
    Clin Chim Acta 409:136-9. 2009
    ..4121C>T, which changes arginine 1270 to a stop codon (R1270X). In conclusion, we describe a case of Tangier disease in association with an unrecognised bleeding tendency, in a man homozygous for a novel ABCA1 gene mutation, R1270X...
  31. doi request reprint Non-alcoholic steatohepatitis-related cirrhosis in a patient with APOB L343V familial hypobetalipoproteinaemia
    Liesl V Heeks
    Department of Core Clinical Pathology and Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital, Perth, Australia
    Clin Chim Acta 421:121-5. 2013
    ....
  32. doi request reprint A new model of care for familial hypercholesterolaemia from Western Australia: closing a major gap in preventive cardiology
    Gerald F Watts
    Lipid Disorders Clinic, Department of Internal Medicine, Royal Perth Hospital, WA 6847, Australia
    Heart Lung Circ 19:419-22. 2010
    ..FH remains underdiagnosed and inadequately treated, with no national strategies for dealing with the problem. We report an executive summary of a comprehensive model of care for FH developed in Western Australia...
  33. ncbi request reprint Liver dysfunction and steatosis in familial hypobetalipoproteinemia
    Amanda J Whitfield
    School of Surgery and Pathology, University of Western Australia, Crawley, Perth, Australia
    Clin Chem 51:266-9. 2005
    ..5 (c.11040T>G) mutation. This unique case shows an unusual combination of underlying disorders that could all be contributing to liver dysfunction and fatty liver...
  34. doi request reprint Familial hypercholesterolemia: epidemiology, Neolithic origins and modern geographic distribution
    Khemanganee E Liyanage
    School of Pathology and Laboratory Medicine, University of Western Australia, Crawley, Western Australia
    Crit Rev Clin Lab Sci 48:1-18. 2011
    ....
  35. doi request reprint Dalcetrapib , a cholesteryl ester transfer protein modulator
    Amanda J Hooper
    Royal Perth Hospital, Department of Core Clinical Pathology and Biochemistry, PathWest Laboratory Medicine WA, Perth, Western Australia
    Expert Opin Investig Drugs 21:1427-32. 2012
    ....
  36. doi request reprint High-resolution melting analysis for detection of familial ligand-defective apolipoprotein B-100 mutations
    Khemanganee E Liyanage
    School of Surgery and Pathology, University of Western Australia, Perth, Australia
    Ann Clin Biochem 45:170-6. 2008
    ..FDB cannot be clinically distinguished from heterozygous LDL-receptor-defective familial hypercholesterolaemia (FH) without genetic testing...
  37. ncbi request reprint Assessment of tocopherol metabolism and oxidative stress in familial hypobetalipoproteinemia
    Michael W Clarke
    Department of Core Clinical Pathology and Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital, Perth, WA, Australia
    Clin Chem 52:1339-45. 2006
    ..We examined the effect of truncated apoB variants on vitamin E metabolism and oxidative stress in persons with FHBL...
  38. ncbi request reprint Monogenic hypocholesterolaemic lipid disorders and apolipoprotein B metabolism
    Amanda J Hooper
    School of Surgery and Pathology, University of Western Australia, Crawley, Australia
    Crit Rev Clin Lab Sci 42:515-45. 2005
    ....
  39. ncbi request reprint Lipid disorders and mutations in the APOB gene
    Amanda J Whitfield
    School of Surgery and Pathology, University of Western Australia, Crawley
    Clin Chem 50:1725-32. 2004
    ..In addition to being the essential structural component of VLDL, apoB-100 is the ligand for LDL-receptor-mediated endocytosis of LDL particles...
  40. pmc Genetic determinants of hepatic steatosis in man
    Amanda J Hooper
    Department of Core Clinical Pathology and Biochemistry, Royal Perth Hospital, Perth, Australia
    J Lipid Res 52:593-617. 2011
    ..Identifying the genetic determinants of hepatic steatosis will lead to a better understanding of the pathogenesis and progression of NAFLD...
  41. doi request reprint A novel missense HGD gene mutation, K57N, in a patient with alkaptonuria
    Jonathan M Grasko
    Department of Core Clinical Pathology and Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital, Perth, Australia
    Clin Chim Acta 403:254-6. 2009
    ..In summary, we describe an alkaptonuric patient and report a novel missense HGD mutation, K57N...
  42. doi request reprint Familial hypercholesterolaemia: a model of care for Australasia
    Gerald F Watts
    Lipid Disorders Clinic, Metabolic Research Centre and Department of Internal Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia
    Atheroscler Suppl 12:221-63. 2011
    ..After initial implementation, the MoC will require critical evaluation, development and appropriate modification...
  43. doi request reprint Anacetrapib, a cholesteryl ester transfer protein inhibitor
    Amanda J Hooper
    Royal Perth Hospital, Department of Core Clinical Pathology and Biochemistry, PathWest Laboratory Medicine WA, Perth, Western Australia
    Expert Opin Investig Drugs 21:103-9. 2012
    ..However, anacetrapib does not appear to exhibit these effects and is being developed as a selective inhibitor of CETP to be orally administered for the treatment of primary hypercholesterolemia and mixed hyperlipidemia...
  44. ncbi request reprint Detection of familial hypercholesterolaemia: a major treatment gap in preventative cardiology
    Timothy R Bates
    Lipid Disorders Clinic and Department of Internal Medicine, Royal Perth Hospital, GPO Box X2213, Perth, Western Australia 6847, Australia
    Heart Lung Circ 17:411-3. 2008
    ..Amongst those with FH, only 38% were on statin therapy and only 22% were treated to National Heart Foundation targets. Detection and treatment of FH represents a major gap in coronary prevention...
  45. doi request reprint Mipomersen, an antisense apolipoprotein B synthesis inhibitor
    Damon A Bell
    Royal Perth Hospital, Department of Core Clinical Pathology and Biochemistry, PathWest Laboratory Medicine, Perth, Western Australia
    Expert Opin Investig Drugs 20:265-72. 2011
    ....
  46. doi request reprint Familial hypobetalipoproteinemia in a Turkish family with hereditary spastic paraplegia
    Amanda J Hooper
    Department of Core Clinical Pathology and Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital, Perth, Australia
    Clin Chim Acta 390:152-5. 2008
    ..8 mmol/L, apoB 0.31 g/L), were heterozygous for a single nucleotide deletion in exon 26 of the APOB gene. This mutation is predicted to form a truncated apoB species of 3545 amino acids, which we have designated apoB-78.2...
  47. doi request reprint Recent developments in the genetics of LDL deficiency
    Amanda J Hooper
    Department of Core Clinical Pathology and Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital, Australia
    Curr Opin Lipidol 24:111-5. 2013
    ..In this review, we discuss the recent developments in the genetics of LDL deficiency...
  48. doi request reprint Late-onset carbamoyl phosphate synthetase 1 deficiency in an adult cured by liver transplantation
    Timothy R Bates
    Department of Internal Medicine, Swan District Hospital, Middle Swan, Western Australia, Australia
    Liver Transpl 17:1481-4. 2011
    ..One year after liver transplantation, the patient had normal plasma ammonia concentrations and had returned to work...
  49. ncbi request reprint The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population
    Amanda J Hooper
    Department of Core Clinical Pathology and Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital, Perth, Australia
    Atherosclerosis 193:445-8. 2007
    ..We sought to determine the frequency and effect of these nonsense variants in an African population...
  50. ncbi request reprint Clomiphene-associated combined hyperlipidemia: a case report
    Melissa J Gillett
    Department of Core Clinical Pathology and Biochemistry, Path West Laboratory Medicine WA, Royal Perth Hospital, Perth, Western Australia, Australia
    J Reprod Med 51:587-90. 2006
    ..Clomiphene is structurally similar to other synthetic estrogen analogs, which are known to induce marked hypertriglyceridemia. There is a paucity of data regarding the effects of clomiphene on lipid metabolism in humans...
  51. ncbi request reprint Inhibition of the apical sodium-dependent bile acid transporter reduces LDL cholesterol and apoB by enhanced plasma clearance of LDL apoB
    Murray W Huff
    Department of Medicine and Biochemistry and The John P Robarts Research Institute, The University of Western Ontario, London, Ontario, Canada
    Arterioscler Thromb Vasc Biol 22:1884-91. 2002
    ..The objective of this study was to determine whether a novel, specific, minimally absorbed ASBT inhibitor (SC-435) decreases LDL cholesterol through the alteration of plasma apoB kinetics...
  52. ncbi request reprint Inhibition of both the apical sodium-dependent bile acid transporter and HMG-CoA reductase markedly enhances the clearance of LDL apoB
    Dawn E Telford
    Robarts Research Institute and Departments of Medicine and Biochemistry, University of Western Ontario, London, Ontario, Canada
    J Lipid Res 44:943-52. 2003
    ..We conclude that SC-435+A potentiates the reduction of LDL-C and LDL apoB due to complementary mechanisms of action...
  53. ncbi request reprint Apolipoprotein A-I-stimulated apolipoprotein E secretion from human macrophages is independent of cholesterol efflux
    Maaike Kockx
    Macrophage Biology Group, Centre for Vascular Research, University of New South Wales, Sydney 2052, Australia
    J Biol Chem 279:25966-77. 2004
    ....
  54. ncbi request reprint Estimating LDL ApoB: infomania or clinical advance?
    John R Burnett
    Clin Chem 54:782-4. 2008
  55. ncbi request reprint Familial hypercholesterolaemia: a look back, a look ahead
    John R Burnett
    Med J Aust 182:552-3. 2005
  56. ncbi request reprint A mild case of abetalipoproteinaemia in association with subclinical hypothyroidism
    Huda A Al-Mahdili
    Department of Clinical Biochemistry, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
    Ann Clin Biochem 43:516-9. 2006
    ..61 + 2T > C) and a single adenine insertion in MTP exon 4 (c.419-420insA) that results in a frameshift and a protein truncated at 140 amino acids...